Skip to main navigation
Main Corporate Nav
About Us
About Us
Board of Directors
Leadership
Partnering
Our History
Pipeline
Pipeline
Parkinson's Disease & Prasinezumab
ATTR Amyloidosis & PRX004
Alzheimer's Disease
Pioneering Neuroscience
Publications
Clinical Trials
Clinical Trials
Prasinezumab Phase 2 Study
PRX004 Phase 1 Study
Expanded Acces Policy
Investors
Investors
Press Releases
Events & Presentations
Financial & Filings
Corporate Governance
Stock information
Analyst Coverage
Careers
Careers
Our Values
Compensation & Benefits
Opportunities
Public House
Contact Us
Contact Us
About Us
Leadership
Board of Directors
Partnering
Our History
About Us
Management
Board of Directors
Partnering
Our History
Pipeline
Parkinson’s Disease & prasinezumab
ATTR Amyloidosis & PRX004
Alzheimer’s Disease
Neuroscience Discovery Programs
Publications
Clinical Trials
Prasinezumab Phase 2 Study
PRX004 Phase 1 Study
Expanded Access Policy
Investors
Press Releases
Events & Presentations
Financials & Filings
Corporate Governance
Stock Information
Analyst Coverage
Careers
Our Values
Compensation & Benefits
Opportunities
Public House
Contact Us
Menu
Menu
Event Details
Investor Relations
Overview
Press Releases
Events & Presentations
Financials & Filings
SEC Filings
Quarterly Results
Key Ratios
Irish Statutory Financial Statements
Corporate Governance
Committee Composition
Stock Information
Analyst Coverage
Shareholder Tools
Phase 2 PASADENA Study Results
Sep 15, 2020
1:30 PM EDT
Listen to webcast
Scroll to top